API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ocular surface pain.
Lead Product(s): Lifitegrast
Therapeutic Area: Ophthalmology Product Name: Xiidra
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch & Lomb Incorporated
Deal Size: $2,500.0 million Upfront Cash: $1,750.0 million
Deal Type: Divestment September 29, 2023
Details:
The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
Lead Product(s): Lifitegrast
Therapeutic Area: Ophthalmology Product Name: Xiidra
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 11, 2023
Details:
Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ocular surface pain.
Lead Product(s): Lifitegrast
Therapeutic Area: Ophthalmology Product Name: Xiidra
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch & Lomb Incorporated
Deal Size: $2,500.0 million Upfront Cash: $1,750.0 million
Deal Type: Divestment June 30, 2023
Details:
Novartis intends to develop the AcuStream technology for potential use with its existing and future front-of-eye therapies, which could include Xiidra® (lifitegrast ophthalmic solution) 5%, a first-in-class prescription LFA 1 antagonist for the treatment of dry eye disease.
Lead Product(s): Lifitegrast
Therapeutic Area: Ophthalmology Product Name: Xiidra
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 30, 2022